Immune checkpoint inhibitors in adjuvant setting after radical resection of melanoma: a meta-analysis of the pivotal trials

Beyond the overall relapse-free survival (RFS) advantage demonstrated in randomized trials (RCT) of adjuvant anti-PD-1 immunotherapy in radically resected stage III–IV melanoma, key issues about subgroups of interest have been raised in recent years, with non-conclusive results when considering sing...

Descripción completa

Detalles Bibliográficos
Autores principales: Bersanelli, Melissa, Petrelli, Fausto, Buti, Sebastiano, Stanganelli, Ignazio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2021
Materias:
Melanoma Immunotherapy SF – Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9122382/
https://www.ncbi.nlm.nih.gov/pubmed/33881961
http://dx.doi.org/10.1080/21645515.2021.1902723

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9122382/
https://www.ncbi.nlm.nih.gov/pubmed/33881961
http://dx.doi.org/10.1080/21645515.2021.1902723

Ejemplares similares